Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
- Gertie J Oostingh1Email author,
- Eudald Casals2,
- Paola Italiani3,
- Renato Colognato4,
- René Stritzinger1,
- Jessica Ponti4,
- Tobias Pfaller1,
- Yvonne Kohl5,
- Daniëlla Ooms6,
- Flavia Favilli3,
- Hilde Leppens6,
- Davide Lucchesi3,
- François Rossi4,
- Inge Nelissen6,
- Hagen Thielecke5,
- Victor F Puntes2, 7,
- Albert Duschl1 and
- Diana Boraschi3
© Oostingh et al; licensee BioMed Central Ltd. 2011
Received: 29 September 2010
Accepted: 9 February 2011
Published: 9 February 2011
With the increasing use of nanomaterials, the need for methods and assays to examine their immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological tests should be used to determine the effects of engineered nanoparticles on human immune responses. However, before assays can be standardised, it is important that suitable methods are established and validated.
In a collaborative work between European laboratories, existing immunological and toxicological in vitro assays were tested and compared for their suitability to test effects of nanoparticles on immune responses. The prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or commercially available as powders. Several problems and challenges were encountered during assay validation, ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical immunotoxicity of solvents and contamination with endotoxin.
The problems that were encountered in the immunological assay systems used in this study, such as chemical or endotoxin contamination and optical interference caused by the dense material, significantly affected the data obtained. These problems have to be solved to enable the development of reliable assays for the assessment of nano-immunosafety.
The potential benefits and the risks associated with the application of nanomaterials have been widely debated in recent years. The need to correctly assess nanoparticle (NP) risks in order to protect workers, consumers and the environment is well accepted in the scientific and regulatory community [1, 2]. Both the human population and the environment may be exposed to nanomaterials during all stages of the NP life cycle: raw material production, transport and storage, industrial use, consumer use, and waste disposal. The consumer use can vary from products like coated textiles or paints, where the presence of nano-products is not clearly stated, to sunscreens, where the NP content is explicitly labelled. In addition, medical use of NPs for diagnostic purposes or as drug delivery backbone represents intentional exposure to significant NP doses. Currently, a variety of methodologies are being discussed and evaluated to perform a complete risk assessment of nanomaterials. There are a number of European legislations that have the objective of implementing laws regarding use of and exposure to nanomaterials [3, 4] including the REACH programme . However, a lack of information on exposure levels, in vitro and in vivo NP effects and the life cycle of these entities make implementation of standards extremely difficult.
Even though a wealth of publications addresses the delicate issue of toxicity of engineered NPs [1, 6, 7], the exact events that occur in the interaction between NPs and the immune system are still largely unknown, even though nanoparticle-induced alterations of the immune system can have important effects on human health . Despite a worldwide effort, results are overall contradictory, in particular when (immuno-) toxicity of NPs in vitro or in vivo is concerned, and no clear-cut information can be provided to the policy-makers, the producers and workers, and the public at large. Results obtained in different laboratories can often not be compared because of a lack of disclosure of experimental details as well as a lack of standardisation of methods and reagents.
An important aspect is that nanoparticle characterisation should also be performed at the point of use, since ageing, storage conditions and contamination can modify their properties in important ways. Alterations in particle characteristics can also occur when nanomaterials get in contact with the human body or with biological entities in the environment. Biological molecules can modify the nanomaterials and cause dissolution, aggregation or, at the very least, coating. The result can be anything from free ions or chemicals released from nanomaterials to micrometer-sized aggregates. Coating, for example by polysaccharides or proteins, may render the materials less harmful but can also change their properties in unexpected ways [9, 10]. Furthermore, association with biological molecules such as endotoxins, can strongly affect the immunological response towards the particles.
For the analysis of the effects of nanoparticles on the immune system, the use of in vivo models can help in identifying possible risks for human health . The adsorption, distribution, metabolism and excretion (ADME) of these materials may play a major role in immunotoxicity and can only be studied in vivo in animal models [12, 13]. However, how well animal models reflect the real-life situation in humans and how well the results from these animal models correspond to the events observed after exposure of human beings to NPs is still to be determined. The use of in vitro assays with human cells could provide relevant information, which can be missed when using animal cells, in particular on the mechanisms of NP-mediated interactions and effects. For example, studies addressing the activation of toll-like receptors (TLR) by nanomaterials [14, 15] should consider the significant differences in TLR expression, regulation and function between man and mouse .
Many publications describe the direct toxicity of NPs on human cells in vitro, using a plethora of different methods that either analyse the number of dead or alive cells or the metabolic capacity of the cells. These methods, however, miss to report the many events that can precede cell death, and overlook the large variety of effects that can take place without causing cell death.
The immune system is the complex of innate and adaptive mechanisms responsible for body's integrity, which can sense external or internal danger signals and initiate an appropriate defence response against such danger. Studying the interaction of NPs with the immune system is of particular relevance in the case of NPs used for medical applications, since they are often injected into the blood stream and come in direct contact with a multitude of immune cells . The innate immune system provides the first line of defence, typically triggering a protective inflammatory response within minutes. If this proves insufficient, the slower adaptive response is induced. Deranged immune responses lead to pathology, both in the case of insufficient activity and in the case of uncontrolled reactions.
Most assays that are currently used to analyse nano-immunotoxicity were originally designed for the analysis of the immunotoxicity of dissolved chemicals. In many instances [8, 18] these assays are not suitable for the purpose of nano-immunotoxicological analysis, and standard assay protocols applied to chemical toxicity analysis often cannot be used. New assays have to be designed for the analysis of nano-immunotoxicity and nano-immunomodulation.
In this study, metal or metal oxide NPs were used, many of which are used as core materials in medical applications. Gold NPs are currently tested for their use in medicine as drug transporters and for diagnostic imaging, i.e. for cancer detection . Cobalt oxide NPs are used in a wide range of applications, such as contrast agents in magnetic resonance imaging , and silver NPs are used as anti-bacterial agents in wound dressings . The study is specifically directed at identifying the problems that nano-immunotoxicologists can encounter when assessing the potential toxic and modulatory effects of NPs for immune cells in culture, in order to set up relevant and reliable assays for nano-immunosafety. To this end, we will focus on human cells that contribute to the innate immune defence mechanisms. These include professional immune cells, such as monocytes/macrophages, and non-professional defence cells, such as epithelial cells of the respiratory and gastro-intestinal tract.
NP synthesis, characterisation and preparation
Synthesis and characterisation
Characteristics of NPs as synthesized and their solvents
Mean Diameter (nm)
5 × 1013
Na Citrate 0.25 mM; oxidised NaBH4 0.3 mM; pH 8
Na Citrate 2.2 mM; pH 7
Na Citrate 0.85 mM; pH 7
Na Citrate 10 mM; pH 7
Silver Oxide (AgO)
Oxidized NaBH4 2.64 mM; pH 9
Iron Oxide (Fe3O4)
Tetramethylammonium Hydroxide (TMAOH) 5 mM; pH 10
Cobalt Oxide (CoO)
TMAOH 1 mM; pH 9
Cerium Oxide (CeO2)
5 × 1013
TMAOH 1 mM; pH 9
1.1 × 109
Na Citrate 20 μM
Cerium Oxide (CeO2)
Cobalt Oxide (CoO)
The 4 nm (mean diameter) Au NPs were synthesized following the procedure described by Jana et al. , based on the fast injection of 2.64 ml ice-cold freshly prepared sodium borohydride 0.1 M (NaBH4, reducing agent) into 200 ml of aqueous solution containing 0.25 mM gold tetrachloroaureate trihydrate (HAuCl4) and 0.25 mM trisodium citrate (stabilising agent), while stirring at room temperature. Other sizes of Au NPs (13 and 20 nm) were obtained with a procedure based on Turkevich et al. , consisting of the fast injection of a solution HAuCl4 to a boiling solution containing trisodium citrate under vigorous stirring. Varying the Au: sodium citrate ratio results in monodispersed Au NPs with different mean diameters . All uncoated Au NPs were loosely coated with the negatively charged citrate ions. Ag NPs synthesis was based on the same Turkevich's method. For the 30 nm Ag NPs, 5 ml of sodium citrate 0.1 M were injected to a boiling solution of 50 ml of silver nitrate (AgNO3) 1 mM and stirred vigorously for 5 min. The resulting solution was cooled down in another vial to avoid deposition of silver on the glass surface. Oxidation of Ag NPs was negligible during the time frame of the experiments. Citrate ions were the coating agent as in the case of Au NPs. Colloidal CoO NPs were obtained after the synthesis of Co metallic NPs in organic solvent and further phase transfer. First, Co NPs of 7 nm mean diameter were prepared following the method described by Puntes et al. , based on the thermal decomposition of cobalt carbonyl (Co2(CO)8) in o-dichlorobenzene in the presence of oleic acid and trioctylphosphine, under controlled Ar-atmosphere. Thereafter, 1 mM tetra-methyl ammonium hydroxide (TMAOH) was used to exchange the NPs surfactant and thus render the particles water-soluble . Under these conditions (exposed to air and fluid) the Co NPs slowly evolve towards cobalt oxide.
The CeO2 particles were synthesized by the nonisothermal precipitation procedure based on Zhou et al.  and Chen et al.  with some modifications. Briefly, 50 ml of cerium (III) nitrate solution (Ce(NO3)3•6H2O) 0.02 M were set at 70°C with a stirring rate of 500 rpm followed by the addition of 25 ml TMAOH 1 M. As soon as the TMAOH was added, the formation of white precipitates was observed. This stage was prolonged for 5 min, to oxidise the Ce(III)-Ce(IV). Right afterwards, the solution was rapidly transferred into a water bath, in which the reaction was continued at 50°C for 20 h. Then, the resulting solution was centrifuged, washed and resuspended in 50 ml TMAOH 1 mM to stabilise the formed CeO2 NPs.
For Fe3O4 NPs, Massart's method was followed [29, 30]. Amounts of 1 mmol iron (II) chloride (FeCl2) and 2 mmol iron (III) chloride (FeCl3) were dissolved in 10 ml deoxygenated water and then added drop wise to 10 ml of a solution of 1 M deoxygenated TMAOH. After 30 min of vigorous stirring under a N2 stream, the Fe3O4 precipitate was washed by soft magnetic decantation, re-dissolved in 0.5 M TMAOH and diluted 100 times to obtain the final stable colloidal solution.
For the characterisation of the particles, TEM images were acquired with a JEOL 1010 Electron Microscope operating at an accelerating voltage of 80 kV. Samples for TEM were prepared by drop casting on carbon coated cooper TEM grids. The grids were left to dry at room temperature. Observations were made on different parts of the grid and with different magnifications and more than 400 particles were computer-analysed and measured for the size distribution.
Z-Potential measurement (Z-Potential) and Dynamic Light Scattering (DLS) measurements were made with a Malvern ZetaSizer Nano ZS Instrument operating at a light source wavelength of 532 nm and a fixed scattering angle of 173° for detection. Aliquots of 0.8 ml of the colloidal NP solutions were placed into the specific cuvette and the software was arranged with the specific parameters of refractive index and absorption coefficient of NP material and solvent viscosity (data required to obtain the correct value for each NP type). Z-Potential (surface charge) measurements are a commonly used tool to determine the stability of a colloidal suspension of electro-statically stabilised NPs. On the other hand, DLS allows the determination of the hydrodynamic diameter of colloidal particles and conjugates, that is the diameter of the sphere with the same Brownian motion as the analysed particle.
X-Ray Diffraction (XRD) spectra were acquired with a PANalytical X'Pert diffractometer that uses a Cu and Co Kα radiation source. Samples for XRD consist of the dry NPs in powder form. For this purpose, destabilisation of the NPs mixing the colloid with a solvent of different polarity was followed by soft centrifugation after which NPs precipitated. The supernatant was discarded, and the pellet of NPs was dried to eliminate all the moisture.
UV-visible spectrophotometry (UV-VIS) spectra were acquired with a Shimadzu UV-2400 spectrophotometer. One ml of the NP solution was placed in a cuvette, and spectral analysis was performed in the 300 nm to 800 nm range. This technique is widely used for metallic NPs, such as gold and silver, which exhibit a characteristic absorbance maximum in the visible range (the Surface Plasmon Resonance, SPR) that changes depending on the size and surface alterations. However, all the materials used absorb in the visible or UV range, making these measurements appropriate in all cases.
In addition, several NPs were obtained from commercial sources. Ag NPs (80 nm) were obtained from BB International Ltd. (Cardiff, UK) as colloidal suspension of 1.1 × 109 NPs/ml (corresponding to 3.1 μg/ml) in water with 20 μM citrate. Magnetite (iron oxide) NPs (100 nm) were provided by Chemicell (Berlin, Germany) as sterile suspension in water with citrate, at the concentration of 50 mg/ml (1.8 × 1015 NPs/ml). Several dry NP powders were purchased from Nanostructured & Amorphous Materials (NanoAmor), Inc., Houston, TX, USA. According to the manufacturer's descriptions, Au nano-powder consisted of black spherical particles with diameters ranging from 50-100 nm. The surface area was 3.3 m2/g and sample purity was stated to be more than 99.99%. The CeO2 nanopowder was synthesized via sol-gel processing and consists of spherical, pale yellow particles with a size range from 15-30 nm, a surface area of 30-50 m2/g and a density of 7.1 g/cm3; the purity was 99.9%. Passivated, black and spherical cobalt oxide (CoO) particles were synthesized via Plasma Chemical Vapour Deposition (CVD). These particles had a diameter of 28 nm, a surface area of 40-60 m2/g, and a density of 8.9 g/cm3; the purity was 99.8% with small amounts of Ni (0.08%) and Fe (0.01%). Iron(II, III)oxide powder (FexOy; NanoAmor) comprised of spherical, reddish brown particles with a diameter of 20-50 nm, a surface area of about 50 m2/g, a density of 5.2 g/cm3 and a purity of more than 98%. The dry particles were resuspended in endotoxin-free phosphate buffered saline to obtain particle suspensions with a final concentration as indicated for the different experiments. For most experiments, a volume of 10 μl of the NP suspension was added to 100 μl cell culture medium, resulting in a 9.1% v/v NP suspension, unless stated otherwise. For all the NP suspensions obtained by adding solvents to dry powders, we invariably observed that the particles aggregated and agglomerated, resulting in NP-derived micrometer scale materials (data not shown). The list of all NPs used in this study is reported in Table 1.
Preparation of NP solvents for biocompatibility in culture conditions
Initial experiments showed that the solvents (NP-free aqueous solution in which NPs are dispersed) used to synthesise and stabilise the particles in solution sometimes had a toxic effect on the different human cell lines used in our studies, even when used at a final concentration of 9.1% v/v. In order to avoid the analysis of chemical toxicity caused by the solvents instead of nanotoxicity, the cytotoxicity of all solvents in the absence of NPs was tested prior to the analysis of NP-induced immuno-toxicity effects. For this purpose, two sets of solvents were prepared and used as controls in the biological tests. One set of solvents was identical to the recipe of synthesis except for the precursor reagents, while the other was a NP solution from which NPs were removed by high-speed centrifugation. As discussed elsewhere , the analysis of these two solvents did not show relevant differences. Only those solvents that did not show any cytotoxic effect on THP-1 and A549 cells, as detected using the commercially available CellTiterBlue test (Promega, Madison, WI), were used for further analysis.
Cell lines, primary cells and culture methods
A549 cell line and transfected reporter cell lines
The adherent human lung epithelial cell line A549 (DSMZ, Braunschweig, Germany) was cultured in RPMI-1640 medium supplemented with L-glutamine (4 mM), penicillin and streptomycin (each at 100 μg/ml) and 10% (v/v) heat-inactivated foetal bovine serum (FBS) (all from PAA Laboratories, Pasching, Austria). Cells were maintained at 37°C in humid air with 5% CO2. Stably transfected A549 cell lines were established and cultured as previously described . In this study, A549 cell lines containing the IL-6 or the IL-8 promoter sequence linked to luciferase were used.
BEAS-2B cell line
Adherent human bronchial epithelial BEAS-2B cells (ATCC, LGC Promochem, Teddington, UK) were originally isolated from normal bronchial epithelium and immortalised in culture with an Ad12SV40 hybrid. The cells were cultured in T-75 flasks pre-coated with a mixture of 0.01 mg/ml human plasma fibronectin (Invitrogen, Paisley, UK), 0.03 mg/ml PureCol™ (Inamed Biomaterials, Fremont, USA) and 0.01 mg/ml bovine serum albumin (Sigma-Aldrich) dissolved in complete growth medium. The latter consisted of bronchial epithelial cell basal medium (BEBM; Lonza, Basel, Switzerland) supplemented with the BulletKit obtained from Lonza. Cells were grown in a humidified atmosphere at 37°C and 5% CO2. Before reaching 80% confluence, cells were sub-cultured using 0.25% (v/v) trypsin/0.53 mM versene solution (LGC Promochem) containing 5 mg/ml polyvinyl-pyrrolidone (Sigma-Aldrich).
THP-1 cell line
THP-1 (ATCC) is a human acute monocytic leukaemia cell line that lacks membrane bound immunoglobulins. THP-1 cells were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine, penicillin and streptomycin (1 IU/ml each), 10 mM HEPES and 10% heat-inactivated FBS (all from PAA Laboratories) and maintained at 37°C in humid atmosphere with 5% CO2.
CaCo-2 cell line
The adherent human gut mucosal epithelial cell line CaCo-2 (human colon carcinoma, Cell Bank ICLC-IST, Genoa, Italy) was cultured in DMEM medium supplemented with 2 mM L-glutamine, 50 μg/ml gentamicin (all from GIBCO, Invitrogen), and 10% heat-inactivated FBS (HyClone, Utah, USA). Cells were maintained at 37°C in humid air with 5% CO2. Before reaching 80%-90% confluence, cells were sub-cultured using 0.25% (v/v) trypsin. Medium was refreshed every 4 days. CaCo-2 cells represent human enterocytes after spontaneous in vitro differentiation. Upon reaching confluence, the proliferation rate gradually slowed until stopping, and cells formed an organised epithelial layer with the morphological and functional characteristics of a differentiated epithelium . Therefore, cells were differentiated by maintaining them in culture for 15 days without passage or manipulation, and used afterwards for experimental purposes in culture medium with 5% (v/v) heat-inactivated human AB serum (Sigma-Aldrich).
Human primary monocytes
Human CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs) obtained from buffy coats of healthy donors (Transfusion Centre, Cisanello Hospital, Pisa, Italy) by magnetic cell separation using the MIDIMACS technique according to the manufacturer's instructions (Miltenyi Biotec, Bergisch-Gladbach, Germany). The monocyte purity (>98%) was assessed by flow cytometry (FACScan; Becton Dickinson, Rutherford, NJ) and validated by microscope observation of like-stained slides stained with a modification of the May-Grünwald-Giemsa staining (Diff Quik; Medion Diagnostics, Düdingen, Switzerland). Cells were cultured in RPMI-1640 - Glutamax-I medium (GIBCO, Invitrogen) supplemented with 50 μg/ml gentamicin and 5% heat-inactivated AB human serum at 37°C in humid air with 5% CO2.
Cell viability, cytotoxicity and cell proliferation assays
Metabolic activity - WST-1 assay
The mitochondrial function of cells exposed to NPs was analysed using the WST-1 assay (Roche Diagnostics, Basel, Switzerland). A549 cells were seeded in a 96-well plate at 1 × 104 cells/well/0.1 ml and incubated overnight. Ag NPs (80 nm; 3.09 μg/ml) were divided in two fractions. One fraction was centrifuged for 15 min at 10,000 rpm, and the pelleted NPs were resuspended in cell culture medium. Another fraction was used on cells directly, without solvent exchange. The solvent recovered after centrifugation was also used as control. To reach the final concentrations (ranging from 155 to 927 ng/ml), the NP suspensions were added to cell culture medium at a volume of 5-30 μl to reach a final volume of 0.1 ml. After 24 h of exposure to NPs, the WST assay was performed as described by the distributor. The net absorbance change at 450 nm taken from the wells of untreated cells was taken as 100% cell viability.
Cell proliferation - BrdU assay
The proliferation rate of the cells exposed to NPs was analysed using the BrdU colorimetric assay kit (Roche Diagnostics). A549 cells were seeded in 96 well plates at 1 × 104 cells/well/0.1 ml medium followed by overnight incubation. Cells were exposed to Ag NPs either suspended in water or re-suspended in culture medium at concentrations ranging from 155 to 927 ng/ml, by adding 5-30 μl of NP suspensions to the wells to reach a final volume of 0.1 ml. After 24 h of exposure, the BrdU assay was performed according to the manufacturer's instructions and analysed at 450 nm. Each experiment included, as control, cells lysed with 1% Triton X-100.
CellTiter-Blue (CTB) cell viability assay
To determine the effects of nanoparticles on cell viability the CTB assay from Promega was used. 100 μl of cells were plated out in 96-well microtiter plates (Corning Incorporated, Corning, NY) at a density of 5 × 103 cells/ml for A549 cells, or 5 × 104 cells/ml for THP-1 cells. A549 cells were plated out one day in advance in flat 96-well plates and left overnight to adhere and obtain their normal morphology. THP-1 cells were plated out on the same day as the particles were added in round bottom 96-well plates. Thereafter, 10 μl of the different NP suspensions at scalar concentrations were applied to the cells (9.1% v/v, at final mass concentrations of 200, 40, 8 and 1.6 μg/ml). The cells were then incubated for 48 h at 37°C in 5% CO2. Thereafter, the CTB-assay was performed according to the manufacturer's protocol and the fluorescence signal of resorufin was detected at 590 nm using a plate-reader (Tecan, Salzburg, Austria).
Toxilight cytotoxicity assay
The Toxilight assay (Lonza, Cologne, Germany) is a bioluminescence-based cytotoxicity assay that quantitatively measures the release of adenylate kinase (AK) from damaged cells. The cells were cultured as described for the CTB assay. After the incubation period, untreated cells (no particles) of 3 wells were lysed with 10 μl 10% Triton-X100 in water (Millipore, Billerica, MA) as a positive control. After 5 minutes incubation, the plates were centrifuged for 5 min at 400 × g. Thereafter the Toxilight assay was performed according to the manufacturer's instructions and luminescence was detected using a plate reader (Tecan).
Cytotox96 non-radioactive cytotoxicity assay
The Cytotox96 assay from Promega is a colorimetric-based cytotoxicity assay that quantitatively measures the release of lactate dehydrogenase (LDH) from damaged cells. The cells were cultured as described for the CTB assay. After the incubation period, untreated cells of 3 wells were lysed with 10 μl of 10% Triton-X100 in water (Millipore) as a positive control. After 5 min incubation the plates were centrifuged for 5 min at 400 × g. The Cytotox96 assay was then performed as described by the manufacturer and measured at 490 nm.
Neutral red cell viability assay
For assessment of effects on cell viability, the neutral red cytotoxicity assay was performed. BEAS-2B cells were seeded in pre-coated 96-well plates by adding to each well 200 μl of a cell suspension at 1 × 105 cells/ml, and the cells were grown to sub-confluence for 48 h. Cells were then exposed to 200 μl of the NP solutions or the corresponding solvents at 9.1% (v/v) in complete growth medium for 24 h. A solution of 1 mM paraquat (PQ) in culture medium was used as positive control. At the end of the exposure period the neutral red cytotoxicity assay was performed based on the INVITTOX protocol n°64 (ECVAM DB-ALM, http://ecvam-dbalm.jrc.ec.europa.eu/). The data, analysed at 540 nm, were expressed as percentage cell viability compared to unexposed control cultures (100% viability).
Cell damage and genotoxicity - micronucleus assay
Heparinised blood was obtained from two individual healthy donors (age <40 years, non-smokers, no medication for at least 2 weeks before donation) by venipuncture in Li-heparin tubes (Monovette®, Sarstedt AG & Co., Nümbrecht, Germany) according to standard medical protocol and with formal consent of the donors. The blood was diluted in RPMI-1640 medium supplemented with 10% FBS, 1.5% phytohaemagglutinin and 1% penicillin-streptomycin, and incubated for 24 h in culture tubes (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ). Blood cells were then exposed to NPs for an additional 48 h, by direct addition in the culture tubes. Wet NPs were used at dilutions 9.1% v/v, and 10-fold dilutions of the original synthesis product (see Table 1). Dry NPs were resuspended in PBS at 2.0 mg/ml and used in culture at 0.2, 2.0, 20, and 200 μg/ml. For each experiment, a negative control (cells incubated with medium), a positive control (Mitomycin C 0.5 μM), and the solvent controls (cells incubated with medium containing solvent used for NP synthesis) were included. Cytochalasin B (6 μg/ml) was added after 44 h of culture (20 h after NP addition), in order to block cytokinesis and obtain binucleated cells, fundamental for the MN evaluation. After 48 h of incubation with NPs (72 h from start), cells were treated with an hypotonic solution for 3 min and subsequently prefixed in acid solution (3:5 methanol:acetic acid), washed with methanol and finally fixed with acid solution (6:1 methanol:acetic acid). The suspension was applied on pre-chilled slides and air-dried. Staining was performed with a 2% Giemsa solution. Slides were coded and analysed using an optical microscope (final magnification 400x). To assess the genetic damage, 2000 binucleated cells for each experimental point were examined, randomly coded, following the scoring criteria adopted by the Human Micronucleus Project . Among these, the number of binucleated micronucleated (BNMN) leukocytes containing one or more micronuclei was counted. Moreover, in order to assess the viability index, 500 cells (mononucleated, binucleated and polynucleated) were scored to calculate the cytokinesis-block proliferation index (CBPI) according to Surralles .
Detection of inflammatory cell activation
Cytokine gene expression by human primary monocytes
Human monocytes were seeded in a 6-well plate in 2 ml medium at the density of 5 × 106 cells/well. NPs were diluted in solvent and added to culture medium at a volume of 200 μl to reach a final concentration starting from 4.55% by volume (higher concentrations could not be used because of endotoxin contamination). Control cells were exposed to the corresponding NP solvents at 9.1% v/v (i.e., 200 μl added to 2 ml). Exposure to NPs was also performed in parallel in the presence of LPS (endotoxin, 50 EU/ml; from E. coli 055:B5; Sigma-Aldrich). Controls in all experiments were medium alone (negative control), and LPS alone (50 EU/ml; positive control). After different times of exposure to NPs, cells were collected and analysed for mRNA expression of cytokine and receptor genes by real-time PCR. Evaluated genes included the inflammatory cytokines IL-1β, IL-18, and the IL-18 receptor IL-18Rα. Total RNA was extracted from 4-5 × 106 human monocytes using the MicroRNeasy Kit (Qiagen, Hilden, Germany). RNA integrity was evaluated with a Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany). Only RNA samples with a RIN (RNA Integrity Number) value between 7 and 10 were used (highest quality intact RNA). Retrotranscription of 500 ng of total RNA was performed with the QuantiTect reverse Transcription Kit (Qiagen), according to manufacturer's instructions. For quantitative or semi-quantitative evaluation of expression, the retro-transcribed cDNA was amplified with a RotorGene 3000 real-time cycler (Corbett Research, Doncaster, Victoria, Australia) as follows: one initial step at 50°C for 2 min and 95°C for 15 min was followed by 40 cycles at 95°C for 15 sec, and 56°C for 30 sec, and 72°C for 30 sec. The reaction mix contained 2.5 μl cDNA, 300 μM of primers, water and Master Mix (QuantiTech Sybr Green PCR Kit, Qiagen) in a final volume of 25 μl. The primers for β-actin (housekeeping gene), IL-1β, IL-18, and IL-18Rα were designed on the sequences published in GenBank in two different exons, and synthesised by Eurofins MWG Synthesis GmbH (Ebersberg, Germany). Expression was calculated in two ways, with comparable results. Semi-quantitative evaluation of expression was calculated as: Efficiency target geneCt target gene/Efficiency reference geneCt reference gene. Where Efficiency is the amplification efficiency, the target gene is the gene under analysis, the reference gene is β-actin, and Ct is the threshold cycle. For a more quantitative calculation, a standard DNA curve was constructed and expression of each target gene (ng/reaction) was calculated as the ratio with expression of β-actin (ng/reaction).
Cytokine production by differentiated CaCo-2 cells
Differentiated CaCo-2 cells were seeded in a 6-well plate at the density of 5 × 105 cells/well in 2 ml medium. NPs suspended in solvent (see Table 1) were added to culture medium at a volume of 200 μl (dilution at 9.1%). Control cells were exposed to the corresponding NP solvents at 9.1% v/v (i.e., 200 μl added to 2 ml). Cultures were prolonged for 15 days (low dose chronic exposure).
Controls in all experiments were medium alone (negative control), the inflammatory cytokine IL-1β (10 ng/ml; positive control), and commercial large Co NPs (originally dry powder of diameter 50-200 nm, depyrogenated and resuspended in endotoxin-free saline, which however were at least partially aggregated upon depyrogenation and addition to culture medium).
Cell culture supernatants were cleared of cellular debris and NPs by high speed centrifugation, and frozen at -80°C until assayed for cytokine production. The multiple analyses of angiogenesis and inflammatory secreted factors were performed by the Human Cytokine Antibody Array Panel A Kit and the Human Angiogenesis Antibody Array Kit (R&D Systems; Minneapolis, MN). The protein production was detected by measuring the ECL chemiluminescence intensity (Pierce, Rockford, IL) using a VersaDoc Imaging System (Bio-Rad Laboratories Inc, UK).
Luciferase assay using stably transfected A549 cell lines
The luciferase assay using different stably transfected A549 cell lines was performed as previously described . Briefly, cells were plated in 96-well plates (100 μl/well) at a density of 5 × 103 per well and left overnight to adhere and reach their normal morphology. On day 2, the cells were exposed to rhTNF-α (20 ng/ml) or left untreated. Subsequently, 10 μl of the NP solutions were added and the cells were incubated for 48 hr. The luciferase assay was performed on cell lysates. Supernatant was removed from the wells and 50 μl passive lysis buffer (Promega) were added for 10 min according to the manufacturer's instructions. Then, 40 μl of the cell lysates were transferred to non-transparent white 96-well microtiter plates (Corning). Forty μl of luciferine (the luciferase substrate) were added to the cell lysate and the luminescence was determined immediately using a plate reader (Tecan).
Experiments were performed twice or more as indicated in the figure legends. Mean values ± the standard deviation (SD) were calculated and data sets were compared using the Student's t-test. A p value < 0.05 was considered as statistically significant.
NP physical state in culture media
NP interference with the optically based assays' readout parameters
Many biological experimental readout parameters are based on transmission, i.e., a detector measures the quantity of transmitted light at a given wavelength, and this measure is translated into an optical density. These systems have been designed for testing transparent matter, such as diluted cell lysates and cell culture media, and cannot be applied to optically dense materials such as NPs without accurate validation. Normally, NPs do not emit light but they can absorb it, thus resulting in optically dense samples. Density depends on their chemistry (e.g., gold absorbs more light than iron oxide), size (larger NPs absorb more than small NPs) and concentration.
The NP density can increase the assay readout, leading to an over-estimation of the optical parameter. For example, in the case of a cell viability analysis that uses formazan, the optical density due to formazan (which is proportional to the number of living cells) can be significantly increased by the presence of NPs, giving the false impression of an improved viability and increased proliferation caused by the NPs [6, 7]. In the case of toxic NPs, the decreased formation of formazan (due to reduced cell metabolism) could be masked by the NPs' optical density, providing a false impression of lack of toxicity. Small NPs (4-15 nm) of Au, Ag, AgO, Fe3O4, CeO2, and CoO, all absorb at the wavelengths used in most biological assay readouts: 340, 380, 405, 440, 540/550 nm (Figure 1, lower panel). In addition, some NPs can inhibit colour formation, thereby mimicking a cytotoxic effect. Indeed, it has been observed that carbon nanotubes can absorb formazan and protect it from metabolisation by the cells. The decreased colour formation, due to the direct effect of nanotubes on the dye rather than to decreased number of living cells, may thus lead to the false interpretation of a cytotoxic effect [40, 41]. The best option, when possible, is to remove NPs before performing the assay (for instance when testing cell supernatants in ELISA assays). Although it has previously been shown that some nanomaterials, such as single walled carbon nanotubes, can indirectly interfere with such assays by adsorbing antibodies or cytokines [42, 43], we have tested the adsorption of different cytokines on the metal and metaloxide particles used in this study and never found a reduction in the cytokine detection signal that could be attributed to cytokine binding to the particles. However, the appropriate controls, including cell free systems, have to be included to ensure the analysis of true NP-induced effects. In those cases for which this may not be possible (e.g., in some viability assays), customised assays using wavelengths of 700-800 nm should be devised, or alternative assays that are not based on optical readouts should be used (e.g., flow cytometry, visual counting of dead cells).
A major issue in devising nano-immunomodulatory assays is to make the NP suspensions compatible with the optimal conditions for cellular survival/growth in culture. Each type of culture medium and additive should be evaluated for possible interference with the endpoint measurements of assays aiming at evaluating cell death/proliferation/metabolic activity, as it is routinely done in assays for drug toxicity. However, additional care is needed in the case of nanotoxicity assessment, since NPs can significantly interact with medium components (e.g., with serum proteins), and this interaction will vary depending on the medium composition and the NP characteristics.
In order to ensure that the effects found in any of the immunological tests were due to an immune-response and not to a loss of cell viability, the effects of NPs on the cell viability were determined using different commercial assays. The CTB assay is based on the ability of living cells to convert a redox-dye into a fluorescent product. The Toxilight assay is a bioluminescence-based cytotoxicity assay that quantitatively measures the release of adenylate kinase (AK) from damaged cells. The Cytotox96 assay is a colorimetric-based cytotoxicity assay that quantitatively measures the release of lactate dehydrogenase (LDH) from damaged cells. Using a combination of these three assays has the advantage that cell viability is determined at different levels, with different reagents and different readout systems.
The optical interference was also observed in the Micronucleus (MN) assay used to assess genotoxicity of NPs on human PBMCs. NPs were added to the PBMCs either in monodispersed suspension (wet) or in powder form (dry). Experiments were carried out based on protocols originally designed to test chemical-induced genotoxicity, which were adapted to NP testing by considering some of the problems occurring (e.g., aggregation and sedimentation) . The use of this protocol showed that genotoxicity of wet NPs could be reliably detected and no obvious toxicity or genotoxicity due to the solvents or to the NP preparations was observed (Additional file 1, Figure S1). Super-imposable results were obtained with cells from different donors, underlining good assay reproducibility (data not shown).
For dry NPs, significant problems occurred during the sample preparation, with the formation of aggregates/agglomerates already occurring upon suspension in cell culture medium. After centrifugation and cell fixation for counting micronuclei in binucleated cells, large black spots were observed adhering to cells that practically covered them and did not allow micronuclei evaluation. The problem was not solved by sonication. At visual inspection, all samples contained large particles, irrespective of sonication, and the correlograms obtained by Dynamic Light Scattering analysis confirmed the high particle sedimentation of particles (data not shown). Therefore, strategies other than sonication are required to prevent NP aggregation/agglomeration.
Immunotoxicity and immunomodulation induced by chemical or biological contaminants
Toxicity due to contaminants can interfere with the correct evaluation of the NP-induced effects. This might be due either to solvents or to endotoxin and other carry-over molecules. It is important to identify possible assay interference of contaminating molecules or, even worse, synergistic interactions between NPs and contaminants.
Solvent immunotoxic and immunomodulatory effects
The chemically synthesized NPs, as used in this study, are in a solvent that is normally not designed to be biocompatible. These solvents are intended to stabilise the particles in solution and avoid aggregation or agglomeration. Addition of solvent to the culture medium may induce direct cytotoxicity, or change the osmolarity and pH of the medium, thereby causing cell damage, and dilute nutrients, which decreases metabolic activity. Four citrate-stabilised monodispersed NP preparations (spherical Au NPs of diameter 4, 13, and 20 nm; and polydispersed Ag NPs of average size 30 nm; Table 1) were examined for their cytotoxic effect on human BEAS-2B lung cells using the neutral red assay. The four NP solutions contained different amounts of sodium citrate, giving final concentrations in the culture medium of 0.02 to 0.9 mM. Among the four NP preparations, only the one containing 0.9 mM sodium citrate (30 nm Ag NPs) showed significant toxicity, which overlapped the effect of the solvent alone, reflecting the effect induced by their respective solvents rather than the type, size and concentration of the NPs (data not shown).
Finally, it should be kept in mind that even when the solvents do not affect the viability of the cells and do not induce/modulate an immune response, there is still the possibility that the solvent and the NPs act in a synergistic manner, inducing in combination a higher or different effect compared to those found when analysing the single compounds.
Immunomodulating effects of endotoxin in NP preparations
Synergy of contaminants with NPs
Synergy between NPs and endotoxin in causing biological effects in human primary monocytes
Gene expression (AU) b
0.77 ± 0.40
0.98 ± 0.20 n.s.
0.49 ± 0.04
0.47 ± 0.13 n.s.
3.57 ± 0.80
3.04 ± 0.03 n.s.
0.65 ± 0.16
1.78 ± 0.37*
0.92 ± 0.11
0.92 ± 0.25 n.s.
0.27 ± 0.12
0.82 ± 0.56 n.s.
0.31 ± 0.05
0.17 ± 0.05 n.s.
18.56 ± 1.86
10.17 ± 2.01*
Assays for detecting inflammatory effects: cytokine production and gene expression
As previously detailed, the presence of NPs (chemical composition, concentration, size and shape) can cause interference with the optical readouts of many assays for cellular functions. To assess the inflammatory effects of NPs, the production of soluble inflammatory cytokines and other factors is a well-established endpoint, which is routinely measured by ELISA. To avoid false positive or negative results caused by the physical presence of NPs in the cell supernatants, several actions can be taken. The first is that of centrifuging the cell supernatants before ELISA to sediment the NPs, a method that works well but that is time-consuming and involves a significant loss of sample volume. Another option is that of using molecular biology methods for detecting cell activation, e.g. measuring expression of inflammatory cytokine genes. Also in this case there might be problems related to the presence of NPs, such as a decreased efficiency of RNA extraction from NP-exposed cells, or a lower quality/integrity of extracted RNA. A solution, which however includes pre-determining which gene we want to look at, is the use of reporter cell lines in which a reporter gene (e.g. GFP or luciferase) is under the control of the promoter of the gene of interest. Luciferase is detected in the cell lysates using a standard luciferase assay, while GFP expression can be seen using a fluorescence microscope, and the presence of NPs can hardly interfere with the detection. Hereafter, we describe a series of problems and propose solutions for assessing cytokine expression/production in response to NPs.
RNA extraction and integrity
RNA recovery and integrity from human monocytes exposed to NPs
RNA recovery (% control ± SD) b
RNA integrity (RIN) c
Au NPs 4 nm
96.3 ± 5.8
78.8 ± 7.7
97.2 ± 3.8
CeO 2 NPs
56.5 ± 4.9 *
97.3 ± 3.4
Use of reporter cell lines
Nano-immunosafety is a key area of investigation for nanotoxicologists who aim at evaluating risks for the human health. Not only direct toxicity on immune cells, but even small alterations in the normal defence functions of our innate/inflammatory or adaptive immune responses could lead to a higher risk of developing diseases. Thus, simple, robust and representative assays are urgently required for assessing the possible impact of NPs on human immune functions. For this reason, the currently used in vitro assays and experimental tools need to be accurately optimised and validated, in order to adapt them for the analysis of NP-induced immune effects. This is not an obvious task, since both NPs and biological entities (e.g., human immune cells) are complex systems highly reactive to changes in their environment. Since the physico-chemical characteristics of their respective environments are significantly different, modifications of the experimental conditions are necessary in order to bring the two systems together, and these may strongly alter the characteristics of the particles and the cells, a fact that commands for a rigorous validation of assay conditions.
A number of factors can affect the in vitro assays used for analysing the effects of NPs on immune cells and immune responses. A first source of variability, even before assays are performed, is represented by the great diversity of NPs used in different laboratories or even in one laboratory at different times. NPs can be synthesized by different methods, yielding products that can vary from batch to batch, contain variable amounts of catalysis residues, be more or less contaminated with biological contaminants, and with characteristics that can change due to the conditions and the time the particles are stored  (data not shown). Particle contamination can strongly affect the outcome of in vitro and in vivo experiments. As an example, toxicity of Diesel exhaust particles was significantly reduced when all chemical and biological contaminants were removed from their surface . NPs used in the present study were suspended in different solvents, mainly containing sodium citrate or TMAOH. In agreement with previous studies , citrate showed a dose-dependent cytotoxic effect on BEAS-2B human primary lung cells. This kind of observation highlights the need for accurate studies addressing the possible confounding effects of chemical contaminants or solvent components on the assessment of true NP-related immune effects. Another type of contamination, of great importance when studying immunomodulating/immunotoxic effects of NPs, is the biological contamination. NP suspensions used in this study were sterile (i.e., devoid of live bacterial contaminations), but nevertheless both NPs and their solvents contained variable levels of endotoxin (LPS, endogenous pyrogen; a component of the bacterial cell wall). Many immune cells (either cell lines or primary cells), in particular monocytes/macrophages, are very sensitive to endotoxin and can be readily activated by trace amounts of it. Endotoxin is a very common contaminant of glassware, culture media and additives (e.g., FBS), which cannot be removed by sterilisation. While cell cultures are routinely controlled for endotoxin contamination, and handled exclusively with endotoxin-free equipment and reagents, NP synthesis is usually performed in chemical labs using non-decontaminated glassware and reagents. The way to effectively remove endotoxin is by incineration (for example by heating to 250°C for 30 minutes), but this treatment is not suitable for NPs as it induces irreversible agglomeration. This only leaves the option open of performing the entire synthesis process in endotoxin-free conditions and with the use of pyrogen-free materials . Endotoxin levels should therefore be measured for each particle preparation, in order to ensure that the effects measured cannot be due to this highly active contaminant. Endotoxin is not the only bacterial compound able to induce inflammatory immune reactions, but its heat stability makes its presence more likely after sterilisation. The availability of several commercial assays makes identification of endotoxin easy, but close care should be taken that the particles do not interfere with the assays . Moreover, the presence of significant amounts of endotoxin may also be an indicator of contamination with bacterial compounds in general, which may go undetected because of lack of suitable assays for their identification.
A major technical problem in the adaptation of immunoassays to the analysis of NP effects is the direct interference of NPs with the assay procedures and readouts. The optical density of NPs and their steric hindrance can interfere with the normal experimental procedures (e.g., RNA extraction, any density gradient-dependent procedure) and, in particular, with the optically-based assay readouts . As shown in the present study, to bypass the risk of misinterpretation of results it is recommended to use multiple assays in parallel and to include a number of controls (particles only, particles plus readout dye, analysis at time point zero, etc.), and/or to test NPs only at dilutions that do not cause interference.
In testing of NP-induced immune effects, the choice of the biological assay is also of central importance. Practical reasons, besides the general task of reducing animal experimentation, command the choice of in vitro assays. Given the complexity of immune responses, assays should be designed in such a way as to represent selected relevant real life situations. For instance, in the case of nanomedicines to be administered intravenously, representative in vitro cellular assays should be based on human blood leukocytes (such as monocytes), which are the first cells to come in contact with the injected NPs, and have biological endpoints representing the early innate/inflammatory type responses (see examples in Table 2). Likewise, in the case of ingested or inhaled material, the response of non-professional defence cells such as human gut and lung epithelial cells can be considered as representative of the real life situation (see for example Figure 5 and 7). Primary cells are the first choice in such assays, as they reproduce the response of normal cells of normal individuals. In most cases, the response of primary cells to stimulation is more sensitive than that of continuous cell lines and, in some instances, also qualitatively different . Thus, whenever possible, primary cells are the best choice for setting up representative assays. This is the case for instance of human monocytes, which are easily accessible (peripheral blood) and which show responses to prototypical stimuli that are remarkably reproducible from donor to donor both qualitatively, quantitatively and kinetically (DB, data not shown). However, the use of primary cells is not always feasible (e.g., in the case of primary lung epithelial cells) and is also hampered by the limited cellular life span, which requires obtaining fresh cells (most likely from different donors) for each assay. This makes standardisation very difficult, because of the difficulty in getting cells and the risk of donor-to-donor variability (except in special cases, such as blood monocytes). As an alternative, the use of cell lines (transformed or tumour cells with unrestrained proliferative capacity) is technically easier and reproducible, thus suitable to standardisation and applicable to a first-line screening of the immunomodulatory effects of NPs. Of course, an absolute requirement is that the selected endpoint (e.g., activation of IL-8 expression) is representative of primary cell activation. In this respect, particular caution should be used in testing the anti-proliferative and cytotoxic effects of NPs. Indeed, transformed and tumour cells have a different cell cycle regulation and cell survival compared to primary cells, making them particularly unsuitable for cytotoxicity assays (apoptosis, necrosis, inhibition of proliferation, etc.). Ideally, every NP effect identified using cell lines should be validated on primary cells, unless the assay has already been validated.
The studies reported here have focussed on in vitro immunoassays, in particular addressing early inflammatory/innate immune cellular responses, as those carried out by epithelial cells (barrier and active innate defence cells) and by monocytes/macrophages (professional innate/inflammatory defence cells). Information on the adsorption, distribution, metabolism and excretion (ADME) of nanomaterials is of main importance in understanding the potential toxicity and also in monitoring the biopharmaceutical effects in nanomedicine [12, 13]. Studies have been performed with a multitude of different nanomaterials to determine the ADME in mice or rat models upon inhalation, injection or dermal application. These studies provide valuable information on the localisation of the nanomaterials in several different tissues, which underlies the distinctive pattern of effects. However, ADME studies cannot provide meaningful information on the features of interaction between nanomaterials and defence cells in tissues and organs, and on the mechanisms of the effects/immune reactions. In contrast, this information can be provided by in vitro experiments with isolated cells or single cell types. The use of single cells allows us to understand the role of each cell type in the observed immune responses, and will shed light on the mechanism behind the effects seen in vivo. Understanding the mechanisms is the starting point for a more focussed approach to optimise the safety of nanomedicines or to reduce the toxicity of nanomaterial-containing products. In addition, the in vitro mechanistic studies may serve as a basis for developing representative assays for assessing immunomodulatory effects of nanomaterials that correlate with the in vivo outcomes. Indeed, the rapid development of the nanotechnological industry has resulted in a huge expansion of the different nanomaterials available, which vary in chemical composition, shape, size, and surface coating. Safety testing for all these new materials with in vivo methods is both economically unfeasible and ethically unacceptable, as large numbers of animals would be required. Thus, standardised in vitro assays with selected cell types may be the best option as screening tools to identify potentially hazardous materials. At present, a comprehensive picture of nanomaterial-induced effects cannot be obtained unless both in vivo and in vitro tools are used.
This work was partially supported by the FP6 project DIPNA (SRTP 032131).
- Boczkowski J, Hoet P: What is new in nanotoxicology? Implications for public health from a brief review of the 2008 literature. Nanotoxicology 2010, 4: 1–14. 10.3109/17435390903428844PubMedView ArticleGoogle Scholar
- Boverhof DR, David RM: Nanomaterial characterisation: considerations and needs for hazard assessment and safety evaluation. Anal Bioanal Chem 2010, 396: 953–961. 10.1007/s00216-009-3103-3PubMedView ArticleGoogle Scholar
- European Commission, Towards a European Strategy for Nanotechnology [http://cordis.europa.eu/nanotechnology/actionplan.htm]
- European Commission, Nanosciences and Nanotechnologies (N&N): an action plan for Europe 2005–2009 [http://ec.europa.eu/research/industrial_technologies/policy_en.html]
- REACH legislation [http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:324:0013:01:EN:HTML]
- Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 2008, 4: 26–49. 10.1002/smll.200700595PubMedView ArticleGoogle Scholar
- Monteiro-Riviere NA, Inman AO, Zhang LW: Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharm 2009, 234: 222–235. 10.1016/j.taap.2008.09.030View ArticleGoogle Scholar
- Dobrovolskaia MA, McNeil SE: Immunological properties of engineered nanomaterials. Nature Nanotech 2007, 2: 469–478. 10.1038/nnano.2007.223View ArticleGoogle Scholar
- Lemarchand C, Gref R, Passirani C, Garcion E, Petri B, Müller R, Costantini D, Couvreur P: Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials 2006, 27: 108–118. 10.1016/j.biomaterials.2005.04.041PubMedView ArticleGoogle Scholar
- Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE: Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharmaceut 2008, 5: 487–495. 10.1021/mp800032fView ArticleGoogle Scholar
- Fischer HC, Chan WCW: Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol 2007, 18: 565–571. 10.1016/j.copbio.2007.11.008PubMedView ArticleGoogle Scholar
- Liang XJ, Chen C, Zhao Y, Jia L, Wang PC: Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Metab 2008, 9: 697–709. 10.2174/138920008786049230PubMed CentralPubMedView ArticleGoogle Scholar
- Hagens WI, Oomen AG, De Jong WH, Cassee FR, Sips AJAM: What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 2007, 49: 217–229. 10.1016/j.yrtph.2007.07.006PubMedView ArticleGoogle Scholar
- Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giralt E, Celeda A, Lloberas J, Puntes V: Peptides conjungated to gold nanoparticles induce macrophage activation. Mol Immunol 2009, 46: 743–748.PubMedView ArticleGoogle Scholar
- Chen HC, Sun B, Tran KK, Shen H: Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials 2011, 32: 1731–1737. 10.1016/j.biomaterials.2010.10.059PubMed CentralPubMedView ArticleGoogle Scholar
- Rehli M: Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002, 23: 375–378. 10.1016/S1471-4906(02)02259-7PubMedView ArticleGoogle Scholar
- Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA: Minireview: Nanoparticles and the immune system. Endocrinology 2010, 151: 458–465. 10.1210/en.2009-1082PubMed CentralPubMedView ArticleGoogle Scholar
- Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, Leppens H, Ponti J, Stritzinger R, Puntes V, Boraschi D, Duschl A, Oostingh GJ: The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events. Nanotoxicology 2010, 4: 52–72. 10.3109/17435390903374001PubMedView ArticleGoogle Scholar
- Jain PK, El-Sayed IH, El-Sayed MA: Au nanoparticles target cancer. Nano Today 2007, 2: 18–29. 10.1016/S1748-0132(07)70016-6View ArticleGoogle Scholar
- Pankhurst QA, Connolly J, Jones SK, Dobson J: Application of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 2003, 36: R167-R181. 10.1088/0022-3727/36/13/201View ArticleGoogle Scholar
- Rai M, Yadav A, Gade A: Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27: 76–83. 10.1016/j.biotechadv.2008.09.002PubMedView ArticleGoogle Scholar
- Jana NR, Gearheart L, Murphy CJ: Seeding growth for size control of 5–40 nm diameter gold nanoparticles. Langmuir 2001, 17: 6782–6786. 10.1021/la0104323View ArticleGoogle Scholar
- Turkevich J, Stevenson PC, Hillier J: A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11: 55–75. 10.1039/df9511100055View ArticleGoogle Scholar
- Frens G: Controlled nucleation for regulation of particle-size in monodisperse gold suspensions. Nature Physical Science 1973, 241: 20–22.View ArticleGoogle Scholar
- Puntes VF, Krishnan KM, Alivisatos AP: Colloidal nanocrystal shape and size control: The case of cobalt. Science 2001, 291: 2115–2117. 10.1126/science.1057553PubMedView ArticleGoogle Scholar
- Euliss LE, Grancharov SG, O'Brien S, Deming TJ, Stucky GD, Murray CB, Held GA: Cooperative assembly of magnetic nanoparticles and block copolypeptides in aqueous media. Nano Letters 2003, 3: 1489–1493. 10.1021/nl034472yView ArticleGoogle Scholar
- Zhou XD, Huebner W, Anderson HU: Room-temperature homogeneous nucleation synthesis and thermal stability of nanometer single crystal CeO 2 . Appl Phys Lett 2002, 80: 3814–3816. 10.1063/1.1481244View ArticleGoogle Scholar
- Chen HI, Chang HY: Synthesis and characterization of nanocrystalline cerium oxide powders by two-stage non-isothermal precipitation. Solid State Commun 2005, 133: 593–598. 10.1016/j.ssc.2004.12.020View ArticleGoogle Scholar
- Jolivet JP, Massart R, Fruchart JM: Synthesis and physicochemical study of non-surfactant magnetic colloids in an aqueous-medium. New J Chemistry 1983, 7: 325–331.Google Scholar
- Massart R: Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE T Magn 1981, 17: 1247–1248. 10.1109/TMAG.1981.1061188View ArticleGoogle Scholar
- Oostingh GJ, Schmittner M, Ehart AK, Tischler U, Duschl A: A high-throughput screening method based on stably transformed human cells was used to determine the immunotoxic effects of fluoranthene and other PAHs. Toxicol In Vitro 2008, 22: 1301–1310. 10.1016/j.tiv.2008.03.003PubMedView ArticleGoogle Scholar
- Meunier V, Bourrié M, Berger Y, Fabre G: The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 1995, 11: 187–94. 10.1007/BF00756522PubMedView ArticleGoogle Scholar
- Bonassi S, Fenech M, Lando C, Lin YP, Ceppi M, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Jia C, Di Giorgio M, Ferguson LR, Fucic A, Lima OG, Hrelia P, Krishnaja AP, Lee TK, Migliore L, Mikhalevich L, Mirkova E, Mosesso P, Müller WU, Odagiri Y, Scarffi MR, Szabova E, Vorobtsova I, Vral A, Zijno A: Human MicroNucleus Project: international database comparison for results with the cytokinesis block micronucleus assay in human lymphocytes: effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei. Environ Mol Mutagen 2001, 37: 31–45. 10.1002/1098-2280(2001)37:1<31::AID-EM1004>3.0.CO;2-PPubMedView ArticleGoogle Scholar
- Surralles J, Xamena N, Creus A, Catalan J, Norppa H, Marcos R: Induction of micronuclei by five pyrethroid insecticides in whole blood and isolated human lymphocytes cultures. Mutat Res 1995, 341: 169–184. 10.1016/0165-1218(95)90007-1PubMedView ArticleGoogle Scholar
- Pfaller T, Puntes V, Casals E, Duschl A, Oostingh GJ: In vitro investigation of immunomodulatory effects caused by engineered inorganic nanoparticles - the impact of experimental design and cell choice. Nanotoxicology 2009, 3: 46–59. 10.1080/17435390802546071View ArticleGoogle Scholar
- Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V: Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4: 3623–3632. 10.1021/nn901372tPubMedView ArticleGoogle Scholar
- Sperling RA, Casals E, Comenge J, Bastus NG, Puntes VP: Inorganic engineered nanoparticles and their impact on the Immune Response. Current Drug Metab 2009, 10: 895–904. 10.2174/138920009790274577View ArticleGoogle Scholar
- Kirchner C, Liedl T, Kudera S, Pellegrino T, Javier AM, Gaub HE, Stölzle S, Fertig N, Parak WJ: Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Letters 2005, 5: 331–338. 10.1021/nl047996mPubMedView ArticleGoogle Scholar
- Allen BL, Kichambare PD, Gou P, Vlasova II, Kapralov AA, Konduru N, Kagan VE, Star A: Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. Nano Letters 2008, 8: 3899–3903. 10.1021/nl802315hPubMedView ArticleGoogle Scholar
- Wörle-Knirsch JM, Pulskamp K, Krug HF: Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Letters 2006, 6: 1261–1268.PubMedView ArticleGoogle Scholar
- Patri AK, Dobrovolskaia MA, Stern ST, McNeil SE: Preclinical characterization of engineered nanoparticles intended for cancer therapeutics. In Nanotechnology for Cancer Therapy. Edited by: Mansoor A. New York: Taylor and Francis; 2007:105–138.Google Scholar
- Casey A, Davoren M, Herzog E, Lyng FM, Byrne HJ, Chambers G: Probing the interaction of single walled carbon nantubes within cell culture medium as a precursor to toxicity testing. Carbon 2007, 45: 34–40. 10.1016/j.carbon.2006.08.009View ArticleGoogle Scholar
- Monteiro-Riviere NA, Inman AO: Challenges for assessing carbon nanomaterial toxicity to the skin. Carbon 2006, 44: 1070–1078. 10.1016/j.carbon.2005.11.004View ArticleGoogle Scholar
- Colognato R, Bonelli A, Ponti J, Farina M, Bergamaschi E, Sabbioni E, Migliore L: Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro . Mutagenesis 2008, 23: 377–382. 10.1093/mutage/gen024PubMedView ArticleGoogle Scholar
- Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE: Ambiguities in applying traditional Limulus Amoebocyte Lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 2010, 5: 555–562. 10.2217/nnm.10.29PubMed CentralPubMedView ArticleGoogle Scholar
- Jones CF, Grainger DW: In vitro assessment of nanomaterial toxicity. Adv Drug Deliver Rev 2009, 61: 438–456. 10.1016/j.addr.2009.03.005View ArticleGoogle Scholar
- Holder AL, Lucas D, Goth-Goldstein R, Koshland CP: Inflammatory response of lung cells exposed to whole, filtered, and hydrocarbon denuded diesel exhaust. Chemosphere 2007, 70: 13–19. 10.1016/j.chemosphere.2007.07.036PubMedView ArticleGoogle Scholar
- Uboldi C, Bonacchi D, Lorenzi G, Hermanns MI, Pohl C, Baldi G, Unger RE, Kirkpatrick CJ: Gold nanoparticles induce cytotoxicity in the alveolar type-II cell lines A549 and NCIH44I. Part Fibre Toxicol 2009, 6: 18. 10.1186/1743-8977-6-18PubMed CentralPubMedView ArticleGoogle Scholar
- Vallhov H, Qin J, Johansson SM, Ahlborg N, Muhammed MA, Scheynius A, Gabrielsson S: The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nanoletters 2006, 6: 1682–1686.View ArticleGoogle Scholar
- Casey A, Herzog E, Davoren M, Lyng FM, Byrne HJ, Chambers G: Spectroscopic analysis confirms the interaction between SWCNT and various dyes commonly used to assess cytotoxicity. Carbon 2007, 45: 1425–1432. 10.1016/j.carbon.2007.03.033View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.